Symmetry Partners LLC Has $202,000 Stock Holdings in Cencora, Inc. (NYSE:COR)

Symmetry Partners LLC decreased its stake in Cencora, Inc. (NYSE:COR) by 87.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 895 shares of the company’s stock after selling 6,086 shares during the period. Symmetry Partners LLC’s holdings in Cencora were worth $202,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD bought a new stake in Cencora during the 1st quarter valued at $2,183,619,000. JPMorgan Chase & Co. bought a new position in shares of Cencora in the first quarter valued at approximately $1,199,695,000. Boston Partners purchased a new position in shares of Cencora during the 1st quarter valued at $1,001,269,000. Capital Research Global Investors purchased a new position in Cencora during the first quarter worth about $650,424,000. Finally, Bessemer Group Inc. purchased a new stake in Cencora in the first quarter valued at approximately $556,245,000. Institutional investors own 97.52% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Leerink Partners cut their price target on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a report on Monday, October 7th. StockNews.com cut shares of Cencora from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 20th. Bank of America reaffirmed a “neutral” rating and set a $245.00 price target (down previously from $275.00) on shares of Cencora in a report on Wednesday, September 18th. Wells Fargo & Company raised their target price on Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 1st. Finally, Evercore ISI cut their price objective on shares of Cencora from $270.00 to $250.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, Cencora has an average rating of “Moderate Buy” and a consensus target price of $259.44.

Cencora Price Performance

NYSE COR traded up $6.19 during trading hours on Friday, hitting $234.27. 1,619,694 shares of the company’s stock traded hands, compared to its average volume of 1,405,605. The firm’s 50-day moving average is $231.39 and its 200-day moving average is $230.71. The company has a market capitalization of $46.16 billion, a PE ratio of 25.44, a PEG ratio of 1.46 and a beta of 0.44. The company has a debt-to-equity ratio of 3.93, a current ratio of 0.89 and a quick ratio of 0.55. Cencora, Inc. has a 52-week low of $184.00 and a 52-week high of $247.66.

Cencora (NYSE:COR) last released its earnings results on Wednesday, July 31st. The company reported $3.34 earnings per share for the quarter, beating the consensus estimate of $3.18 by $0.16. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The company had revenue of $74.20 billion during the quarter, compared to the consensus estimate of $73.32 billion. During the same period in the previous year, the company posted $2.92 EPS. Cencora’s revenue was up 10.8% compared to the same quarter last year. Equities analysts forecast that Cencora, Inc. will post 13.64 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Silvana Battaglia sold 1,473 shares of the business’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total transaction of $357,482.37. Following the sale, the executive vice president now owns 10,948 shares of the company’s stock, valued at approximately $2,656,970.12. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Cencora news, Chairman Steven H. Collis sold 21,509 shares of the firm’s stock in a transaction dated Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total value of $5,071,822.20. Following the transaction, the chairman now directly owns 285,088 shares of the company’s stock, valued at $67,223,750.40. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Silvana Battaglia sold 1,473 shares of the business’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total value of $357,482.37. Following the transaction, the executive vice president now directly owns 10,948 shares in the company, valued at $2,656,970.12. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 15.80% of the stock is owned by company insiders.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.